Aberrant Crypt Foci: The Case for Inclusion as a Biomarker for Colon Cancer

Aberrant crypt foci (ACF) are one of the earliest histopathological manifestations of colon cancer. In this review, we critically present the molecular, cellular, histopathological, and chemopreventive evidence that ACF are relevant biomarkers for colon cancer. The laboratory and clinical evidence a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wargovich, Michael J., Brown, Vondina R., Morris, Jay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3837333/
https://www.ncbi.nlm.nih.gov/pubmed/24281183
http://dx.doi.org/10.3390/cancers2031705
_version_ 1782292426736533504
author Wargovich, Michael J.
Brown, Vondina R.
Morris, Jay
author_facet Wargovich, Michael J.
Brown, Vondina R.
Morris, Jay
author_sort Wargovich, Michael J.
collection PubMed
description Aberrant crypt foci (ACF) are one of the earliest histopathological manifestations of colon cancer. In this review, we critically present the molecular, cellular, histopathological, and chemopreventive evidence that ACF are relevant biomarkers for colon cancer. The laboratory and clinical evidence are highly suggestive that ACF are in the pathway leading to colon cancer, but not all ACF will do so. The possible fate and outcome of ACF in the progression toward colon cancer may be dependent on a number of features that define their predictive power for the prevention or progression of cancer.
format Online
Article
Text
id pubmed-3837333
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-38373332013-11-22 Aberrant Crypt Foci: The Case for Inclusion as a Biomarker for Colon Cancer Wargovich, Michael J. Brown, Vondina R. Morris, Jay Cancers (Basel) Review Aberrant crypt foci (ACF) are one of the earliest histopathological manifestations of colon cancer. In this review, we critically present the molecular, cellular, histopathological, and chemopreventive evidence that ACF are relevant biomarkers for colon cancer. The laboratory and clinical evidence are highly suggestive that ACF are in the pathway leading to colon cancer, but not all ACF will do so. The possible fate and outcome of ACF in the progression toward colon cancer may be dependent on a number of features that define their predictive power for the prevention or progression of cancer. MDPI 2010-09-16 /pmc/articles/PMC3837333/ /pubmed/24281183 http://dx.doi.org/10.3390/cancers2031705 Text en © 2010 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Wargovich, Michael J.
Brown, Vondina R.
Morris, Jay
Aberrant Crypt Foci: The Case for Inclusion as a Biomarker for Colon Cancer
title Aberrant Crypt Foci: The Case for Inclusion as a Biomarker for Colon Cancer
title_full Aberrant Crypt Foci: The Case for Inclusion as a Biomarker for Colon Cancer
title_fullStr Aberrant Crypt Foci: The Case for Inclusion as a Biomarker for Colon Cancer
title_full_unstemmed Aberrant Crypt Foci: The Case for Inclusion as a Biomarker for Colon Cancer
title_short Aberrant Crypt Foci: The Case for Inclusion as a Biomarker for Colon Cancer
title_sort aberrant crypt foci: the case for inclusion as a biomarker for colon cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3837333/
https://www.ncbi.nlm.nih.gov/pubmed/24281183
http://dx.doi.org/10.3390/cancers2031705
work_keys_str_mv AT wargovichmichaelj aberrantcryptfocithecaseforinclusionasabiomarkerforcoloncancer
AT brownvondinar aberrantcryptfocithecaseforinclusionasabiomarkerforcoloncancer
AT morrisjay aberrantcryptfocithecaseforinclusionasabiomarkerforcoloncancer

Ejemplares similares